Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TBI-1301 |
Synonyms | |
Therapy Description |
TBI-1301 is a preparation of T-cells modified to express a T-cell receptor that targets NY-ESO-1, which potentially inhibits tumor growth (J Clin Onc 2019 37:15_suppl, 2537, PMID: 37792433). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TBI-1301 | mipetresgene autoleucel | TBI-1301 is a preparation of T-cells modified to express a T-cell receptor that targets NY-ESO-1, which potentially inhibits tumor growth (J Clin Onc 2019 37:15_suppl, 2537, PMID: 37792433). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02869217 | Phase I | Cyclophosphamide + Fludarabine TBI-1301 | Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | Active, not recruiting | CAN | 0 |